KLH 2109

Drug Profile

KLH 2109

Alternative Names: KLH-2109; OBE-2109

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; ObsEva
  • Class Antihormones
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis; Uterine leiomyoma

Most Recent Events

  • 06 Jul 2016 US FDA approves IND application for KLH 2109 in Endometriosis
  • 01 Jun 2016 Phase-II clinical trials in Endometriosis in Poland after June 2016 (PO) (NCT02778399)
  • 01 Jun 2016 Phase-II clinical trials in Endometriosis in USA (PO) (NCT02778399)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top